Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR
Abstract Objective To evaluate the incidence, clinical laboratory characteristics, and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR. Methods We collected a total of 359 Ph‐negative MPN patients with classical mutations in driver genes JAK2, MPL, or...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.7123 |
| _version_ | 1797205649122131968 |
|---|---|
| author | Zhanlong Wang Xin Tian Jinyu Ma Yuhui Zhang Wenru Ta Yifan Duan Fengli Li Hong Zhang Long Chen Shaobin Yang Enbin Liu Yani Lin Weiping Yuan Kun Ru Jie Bai |
| author_facet | Zhanlong Wang Xin Tian Jinyu Ma Yuhui Zhang Wenru Ta Yifan Duan Fengli Li Hong Zhang Long Chen Shaobin Yang Enbin Liu Yani Lin Weiping Yuan Kun Ru Jie Bai |
| author_sort | Zhanlong Wang |
| collection | DOAJ |
| description | Abstract Objective To evaluate the incidence, clinical laboratory characteristics, and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR. Methods We collected a total of 359 Ph‐negative MPN patients with classical mutations in driver genes JAK2, MPL, or CALR, and divided them into two groups based on whether they had additional atypical variants of driver genes JAK2, MPL, or CALR: 304 patients without atypical variants of driver genes and 55 patients with atypical variants of driver genes. We analyzed the relevant characteristics of these patients. Results This study included 359 patients with Ph‐negative MPNs with JAK2, MPL, or CALR classical mutations and found that 55 (15%) patients had atypical variants of JAK2, MPL, or CALR. Among them, 28 cases (51%) were male, and 27 (49%) were female, with a median age of 64 years (range, 21–83). The age of ET patients with atypical variants was higher than that of ET patients without atypical variants [70 (28–80) vs. 61 (19–82), p = 0.03]. The incidence of classical MPL mutations in ET patients with atypical variants was higher than in ET patients without atypical variants [13.3% (2/15) vs. 0% (0/95), p = 0.02]. The number of gene mutations in patients with atypical variants of driver genes PV, ET, and Overt‐PMF is more than in patients without atypical variants of PV, ET, and Overt‐PMF [PV: 3 (2–6) vs. 2 (1–7), p < 0.001; ET: 4 (2–8) vs. 2 (1–7), p < 0.05; Overt‐PMF: 5 (2–9) vs. 3 (1–8), p < 0.001]. The incidence of SH2B3 and ASXL1 mutations were higher in MPN patients with atypical variants than in those without atypical variants (SH2B3: 16% vs. 6%, p < 0.01; ASXL1: 24% vs. 13%, p < 0.05). Conclusion These data indicate that classical mutations of JAK2, MPL, and CALR may not be completely mutually exclusive with atypical variants of JAK2, MPL, and CALR. In this study, 30 different atypical variants of JAK2, MPL, and CALR were identified, JAK2 G127D being the most common (42%, 23/55). Interestingly, JAK2 G127D only co‐occurred with JAK2V617F mutation. The incidence of atypical variants of JAK2 in Ph‐negative MPNs was much higher than that of the atypical variants of MPL and CALR. The significance of these atypical variants will be further studied in the future. |
| first_indexed | 2024-04-24T08:54:28Z |
| format | Article |
| id | doaj.art-8dab39cc7c154bb2b77b63b80e4e3d86 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-24T08:54:28Z |
| publishDate | 2024-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-8dab39cc7c154bb2b77b63b80e4e3d862024-04-16T08:48:34ZengWileyCancer Medicine2045-76342024-04-01137n/an/a10.1002/cam4.7123Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALRZhanlong Wang0Xin Tian1Jinyu Ma2Yuhui Zhang3Wenru Ta4Yifan Duan5Fengli Li6Hong Zhang7Long Chen8Shaobin Yang9Enbin Liu10Yani Lin11Weiping Yuan12Kun Ru13Jie Bai14Department of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaSino‐US Diagnostics Lab Tianjin Enterprise Key Laboratory of AI‐aided Hematopathology Diagnosis Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaSino‐US Diagnostics Lab Tianjin Enterprise Key Laboratory of AI‐aided Hematopathology Diagnosis Tianjin ChinaSino‐US Diagnostics Lab Tianjin Enterprise Key Laboratory of AI‐aided Hematopathology Diagnosis Tianjin ChinaSino‐US Diagnostics Lab Tianjin Enterprise Key Laboratory of AI‐aided Hematopathology Diagnosis Tianjin ChinaSino‐US Diagnostics Lab Tianjin Enterprise Key Laboratory of AI‐aided Hematopathology Diagnosis Tianjin ChinaSino‐US Diagnostics Lab Tianjin Enterprise Key Laboratory of AI‐aided Hematopathology Diagnosis Tianjin ChinaSino‐US Diagnostics Lab Tianjin Enterprise Key Laboratory of AI‐aided Hematopathology Diagnosis Tianjin ChinaState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin ChinaSino‐US Diagnostics Lab Tianjin Enterprise Key Laboratory of AI‐aided Hematopathology Diagnosis Tianjin ChinaDepartment of Hematology The Second Hospital of Tianjin Medical University Tianjin ChinaAbstract Objective To evaluate the incidence, clinical laboratory characteristics, and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR. Methods We collected a total of 359 Ph‐negative MPN patients with classical mutations in driver genes JAK2, MPL, or CALR, and divided them into two groups based on whether they had additional atypical variants of driver genes JAK2, MPL, or CALR: 304 patients without atypical variants of driver genes and 55 patients with atypical variants of driver genes. We analyzed the relevant characteristics of these patients. Results This study included 359 patients with Ph‐negative MPNs with JAK2, MPL, or CALR classical mutations and found that 55 (15%) patients had atypical variants of JAK2, MPL, or CALR. Among them, 28 cases (51%) were male, and 27 (49%) were female, with a median age of 64 years (range, 21–83). The age of ET patients with atypical variants was higher than that of ET patients without atypical variants [70 (28–80) vs. 61 (19–82), p = 0.03]. The incidence of classical MPL mutations in ET patients with atypical variants was higher than in ET patients without atypical variants [13.3% (2/15) vs. 0% (0/95), p = 0.02]. The number of gene mutations in patients with atypical variants of driver genes PV, ET, and Overt‐PMF is more than in patients without atypical variants of PV, ET, and Overt‐PMF [PV: 3 (2–6) vs. 2 (1–7), p < 0.001; ET: 4 (2–8) vs. 2 (1–7), p < 0.05; Overt‐PMF: 5 (2–9) vs. 3 (1–8), p < 0.001]. The incidence of SH2B3 and ASXL1 mutations were higher in MPN patients with atypical variants than in those without atypical variants (SH2B3: 16% vs. 6%, p < 0.01; ASXL1: 24% vs. 13%, p < 0.05). Conclusion These data indicate that classical mutations of JAK2, MPL, and CALR may not be completely mutually exclusive with atypical variants of JAK2, MPL, and CALR. In this study, 30 different atypical variants of JAK2, MPL, and CALR were identified, JAK2 G127D being the most common (42%, 23/55). Interestingly, JAK2 G127D only co‐occurred with JAK2V617F mutation. The incidence of atypical variants of JAK2 in Ph‐negative MPNs was much higher than that of the atypical variants of MPL and CALR. The significance of these atypical variants will be further studied in the future.https://doi.org/10.1002/cam4.7123atypical variantclassical mutationco‐existencedriver genesmyeloproliferative neoplasms |
| spellingShingle | Zhanlong Wang Xin Tian Jinyu Ma Yuhui Zhang Wenru Ta Yifan Duan Fengli Li Hong Zhang Long Chen Shaobin Yang Enbin Liu Yani Lin Weiping Yuan Kun Ru Jie Bai Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR Cancer Medicine atypical variant classical mutation co‐existence driver genes myeloproliferative neoplasms |
| title | Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR |
| title_full | Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR |
| title_fullStr | Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR |
| title_full_unstemmed | Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR |
| title_short | Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR |
| title_sort | clinical laboratory characteristics and gene mutation spectrum of ph negative mpn patients with atypical variants of jak2 mpl or calr |
| topic | atypical variant classical mutation co‐existence driver genes myeloproliferative neoplasms |
| url | https://doi.org/10.1002/cam4.7123 |
| work_keys_str_mv | AT zhanlongwang clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT xintian clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT jinyuma clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT yuhuizhang clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT wenruta clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT yifanduan clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT fenglili clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT hongzhang clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT longchen clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT shaobinyang clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT enbinliu clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT yanilin clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT weipingyuan clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT kunru clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr AT jiebai clinicallaboratorycharacteristicsandgenemutationspectrumofphnegativempnpatientswithatypicalvariantsofjak2mplorcalr |